Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Charles T. Van-Buren"'
Autor:
Ahmed F. Mohamed, Robert Todd, Nesrine S. El Sayed, Mostafa A. Rabie, Charles T. Van Buren, Salwa A. Elgebaly, Lamiaa A. Ahmed, Robert Poston
Publikováno v:
Circulation. 142
Introduction: Demand ischemia causes irreversible myocardial injury (MI) through exhaustion of cellular adenosine triphosphate (ATP). We demonstrated that enhancing myocardial ATP stores during ischemia using Cyclocreatine Phosphate (CCrP), prevents
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08d6467eda5e8f76800bb9238da78c84
https://doi.org/10.1161/circ.142.suppl_3.13311
https://doi.org/10.1161/circ.142.suppl_3.13311
Autor:
Andre Smith, Vanessa Moreno, Shawn Balark, Amitava Dasgupta, Marilyn Sonilal, Charles T. Van Buren, Neelam Tejpal
Publikováno v:
Journal of Clinical Laboratory Analysis. 25:207-211
United States Food and Drug Administration (FDA) in 2010 approved the use of immunosuppressant drug everolimus, which requires therapeutic drug monitoring in whole blood. Taking advantage of structural similarity between sirolimus and everolimus we a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5d13e4e81657239c772c4b61e325b38
https://doi.org/10.1002/jcla.20459
https://doi.org/10.1002/jcla.20459
Autor:
L. Schoenberg, Richard J. Knight, Hemangshu Podder, Martin Villa, Maria Welsh, Charles T. Van Buren, Robert Laskey, Ronald H. Kerman, Barry D. Kahan, Carlos Benavides, Stephen M. Katz
Publikováno v:
Clinical Transplantation. 21:460-465
Aim: As sirolimus has been implicated in impaired wound healing, the aim of this study was to evaluate risk factors for wound complications after renal transplantation in patients treated with this drug de novo. Methods: This single center retrospect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5586098ccacefed3a91429ca8ced8420
https://doi.org/10.1111/j.1399-0012.2007.00668.x
https://doi.org/10.1111/j.1399-0012.2007.00668.x
Autor:
Stephen M. Katz, Charles T. Van Buren, L. Schoenberg, Richard J. Knight, Yarkın Kamil Yakupoğlu, Barry D. Kahan, Deijan Lai
Publikováno v:
Transplantation. 80:749-758
Background Malignancies, a well-known complication of immunosuppressive therapy in renal transplant recipients, represent an important cause of long-term morbidity and mortality. One approach to addressing this problem is identifying agents that disp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad8a8ce6bf6fb92bd902b8d8ca566baa
https://doi.org/10.1097/01.tp.0000173770.42403.f7
https://doi.org/10.1097/01.tp.0000173770.42403.f7
Autor:
Richard J. Knight, Charles T. Van Buren, Ronald H. Kerman, H Podder, Stephen M. Katz, Barry D. Kahan, L. Schoenberg
Publikováno v:
Transplantation. 78:904-910
Background. We previously reported that the use of basiliximab together with sirolimus permits a window of recovery from delayed graft function before the introduction of reduced-dose cyclosporine. The present study reviews our experience with the su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16319ca3f18e32d850a287167985a0b5
https://doi.org/10.1097/01.tp.0000134399.10352.e4
https://doi.org/10.1097/01.tp.0000134399.10352.e4
Autor:
Steven M. Katz, Stanislaw M. Stepkowski, Charles T. Van Buren, Murat Kilic, Barry D. Kahan, Joseph A. Tami, Maria Welsh, William R. Shanahan
Publikováno v:
Transplantation. 78:858-863
Background. ISIS 2302, an antisense oligonucleotide that inhibits the expression of human intercellular adhesion molecule (ICAM)-1, was evaluated in combination with a cyclosporine (CsA)-prednisone (Pred) regimen first in a phase I safety and pharmac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::122db9fde66e29de7c053b64f4b11608
https://doi.org/10.1097/01.tp.0000128857.77893.d2
https://doi.org/10.1097/01.tp.0000128857.77893.d2
Autor:
Ronald N. Ehrle, Roger Durand, Phillip J. Decker, Kimberly D. Davis, Samuel M. Holtzman, Teresa J. Shafer, Charles T. Van Buren, Nicholas J. Crafts
Publikováno v:
Progress in Transplantation. 14:250-263
Purpose Daily presence of organ procurement organization staff in level I trauma centers combined with early family contact and interaction can increase donation rates. Methods A successful in-house coordinator program already in place at 2 level I t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17a12bc462f7b45c3c8600cc1afa1602
https://doi.org/10.7182/prtr.14.3.m53x682544262207
https://doi.org/10.7182/prtr.14.3.m53x682544262207
Autor:
Samuel M. Holtzman, Kimberly D. Davis, Teresa J. Shafer, Roger Durand, Nicholas J. Crafts, Charles T. Van Buren
Publikováno v:
Transplantation. 75:1330-1335
Background. Of 5810 acute care hospitals in the United States, only 3.9% (231) are Level 1 Trauma Centers (L1TCs). L1TCs have a significant number of potential organ donors (PODs). Placement of Organ Procurement Organization (OPO) staff, In House Coo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b34c6f53c516254212b105c7f4ba06b
https://doi.org/10.1097/01.tp.0000060532.70301.32
https://doi.org/10.1097/01.tp.0000060532.70301.32
Autor:
B.D Kahan, Stephen M. Katz, Hemangshu Podder, Charles T. Van Buren, Ronald H. Kerman, Richard J. Knight, Scott Zela
Publikováno v:
Transplantation. 75:1301-1306
BACKGROUND We investigated a novel immunosuppressive protocol including thymoglobulin induction in combination with sirolimus and corticosteroids, followed by introduction of markedly reduced exposures to cyclosporine to prevent pancreas-transplant r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::102dbc6b4f8f9b9dfb3de7f7dfbf9f7d
https://doi.org/10.1097/01.tp.0000061768.98058.ec
https://doi.org/10.1097/01.tp.0000061768.98058.ec
Publikováno v:
Transplantation. 73:756-760
Objective We sought to examine factors that predisposed 1.5% (10/672) of renal transplant recipients treated with a cyclosporine (CsA)/sirolimus (SRL)/steroid immunosuppressive regimen to develop hemolytic uremic syndrome (HUS). Methods Two cohorts o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39c13aea4798b236b3092907483c246f
https://doi.org/10.1097/00007890-200203150-00017
https://doi.org/10.1097/00007890-200203150-00017